UPC Analytics
ENDE
Overview · Filed: Jun 6, 2023

UPC_CFI_75/2023

METHOD OF PRODUCING RETINAL PIGMENT EPITHELIAL CELL

RevocationMain Revocation ActionMunich CDRevocationCase ClosedSettled at: Pre-merits
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE
Reps: Mark Didmon (Potter Clarkson)

Respondents

  • Healios K.K
  • Riken
  • Osaka University
Reps: James Nicholls (JA Kemp); Pamela Tuxworth (JA Kemp)
Judges
  • Ulrike Voß
  • Andras Kupecz
  • Paolo Gerli
Patents
  • EP3056563
  • EP 3 056 563
  • EP 3 056 564
CPC codes: A61P27/02, C12N2501/727, C12N2506/45, C12N2533/52, A61K9/0048, A61K35/30, C12N2509/00, C12N5/0621

Technology area: Biotech · Cell Therapy

Sector: Biotechnology

Outcome
SettledSettled
Filed: Jun 6, 2023
First decided: Sep 21, 2023
Last decision: Mar 18, 2024
Language: English
Settled at: Pre-merits — settled commercially

Order from the Munich Central Division (Section) dated 23 July 2024 disposing of two revocation actions brought by Astellas Institute for Regenerative Medicine against Healios K.K., Riken and Osaka University. Both parties submitted a unanimous application under R. 360 RoP declaring that they concluded the actions by settlement and that the actions were devoid of purpose. The court held that parties may settle without seeking a confirmatory court decision under R. 365 RoP and declared the proceedings closed. A 20% reimbursement of court fees was granted under R. 370.9(c) RoP. Headnotes clarify that settlement-based closures are not limited to the formal R. 365 confirmation procedure.

Open on UPC Registry